Identification of Key Genes Involved in Diabetic Peripheral Neuropathy Progression and Associated with Pancreatic Cancer

References

• Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013;93(1):137–188. doi:10.1152/physrev.00045.2011
   PubMed Web of Science ®Google Scholar
• Andersen DK, Andren-Sandberg Å, Duell EJ, et al. Pancreatitis-diabetes-pancreatic cancer. Pancreas. 2013;42(8):1227–1237. doi:10.1097/MPA.0b013e3182a9ad9d
   PubMed Web of Science ®Google Scholar
• Edwards JL, Vincent AM, Cheng HT, Feldman EL. Diabetic neuropathy: mechanisms to management. Pharmacol Therapeut. 2008;120(1):1–34. doi:10.1016/j.pharmthera.2008.05.005
   PubMed Web of Science ®Google Scholar
• Vincent AM, Calabek B, Roberts L, Feldman EL. Biology of diabetic neuropathy. Handb Clin Neurol. 2013;115:591.
   PubMedGoogle Scholar
• Vincent AM, Callaghan BC, Smith AL, Feldman EL. Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol. 2011;7(10):573–583. doi:10.1038/nrneurol.2011.137
   PubMed Web of Science ®Google Scholar
• Stolzenberg-Solomon RZ, Graubard BI, Chari S, et al. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. JAMA. 2005;294(22):2872–2878. doi:10.1001/jama.294.22.2872
   PubMed Web of Science ®Google Scholar
• Choi Y, Kim T, Oh D, et al. The impact of diabetes mellitus and metformin treatment on survival of patients with advanced pancreatic cancer undergoing chemotherapy. Cancer Res Treat. 2016;48(1):171–179. doi:10.4143/crt.2014.292
   PubMedGoogle Scholar
• Sadeghi N, Abbruzzese JL, Yeung SCJ, Hassan M, Li D. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res. 2012;18(10):2905–2912. doi:10.1158/1078-0432.CCR-11-2994
   PubMed Web of Science ®Google Scholar
• Luo L, Zhou WH, Cai JJ, et al. Gene expression profiling identifies downregulation of the neurotrophin-mapk signaling pathway in female diabetic peripheral neuropathy patients. J Diabetes Res. 2017;2017:8103904. doi:10.1155/2017/8103904
   PubMed Web of Science ®Google Scholar
• Zhang G, Schetter A, He P, et al. DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma. PLoS One. 2012;7(2):e31507. doi:10.1371/journal.pone.0031507
   PubMed Web of Science ®Google Scholar
• Zhang G, He P, Tan H, et al. Integration of metabolomics and transcriptomics revealed a fatty acid network exerting growth inhibitory effects in human pancreatic cancer. Clin Cancer Res. 2013;19(18):4983–4993. doi:10.1158/1078-0432.CCR-13-0209
   PubMed Web of Science ®Google Scholar
• Kiss K, Baghy K, Spisák S, et al. Chronic hyperglycemia induces trans-differentiation of human pancreatic stellate cells and enhances the malignant molecular communication with human pancreatic cancer cells. PLoS One. 2015;10(5):e128059. doi:10.1371/journal.pone.0128059
   Google Scholar
• Nagy Á, Lánczky A, Menyhárt O, Győrffy B. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci Rep-Uk. 2018;8(1):9227.
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102. doi:10.1093/nar/gkx247
   PubMed Web of Science ®Google Scholar
• Vasaikar SV, Straub P, Wang J, Zhang B. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2018;46(D1):D956–D963. doi:10.1093/nar/gkx1090
   PubMed Web of Science ®Google Scholar
• Liao WC, Tu YK, Wu MS, Lin JT, Wang HP, Chien KL. Blood glucose concentration and risk of pancreatic cancer: systematic review and dose-response meta-analysis. BMJ. 2015;350:g7371. doi:10.1136/bmj.g7371
   PubMedGoogle Scholar
• Fujita H, Ohuchida K, Mizumoto K, et al. alpha-smooth muscle actin expressing stroma promotes an aggressive tumor biology in pancreatic ductal adenocarcinoma. Pancreas. 2010;39(8):1254–1262. doi:10.1097/MPA.0b013e3181dbf647
   PubMedGoogle Scholar
• Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4(7):499–511. doi:10.1038/nri1391
   PubMed Web of Science ®Google Scholar
• Dasu MR, Devaraj S, Park S, Jialal I. Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed Type 2 diabetic subjects. Diabetes Care. 2010;33(4):861–868. doi:10.2337/dc09-1799
   PubMed Web of Science ®Google Scholar
• Zhu T, Meng Q, Ji J, Lou X, Zhang L. Toll-like receptor 4 and tumor necrosis factor-alpha as diagnostic biomarkers for diabetic peripheral neuropathy. Neurosci Lett. 2015;585:28–32. doi:10.1016/j.neulet.2014.11.020
   PubMedGoogle Scholar
• Chu HX, Arumugam TV, Gelderblom M, Magnus T, Drummond GR, Sobey CG. Role of CCR2 in inflammatory conditions of the central nervous system. J Cereb Blood Flow Metab. 2014;34(9):1425–1429. doi:10.1038/jcbfm.2014.120
   PubMed Web of Science ®Google Scholar
• Zhang Z, Dong Y, Lu Y, Cao S, Zhao Z, Gao Y. Chemokine CCL2 and its receptor CCR2 in the medullary dorsal horn are involved in trigeminal neuropathic pain. J Neuroinflamm. 2012;9(1):136. doi:10.1186/1742-2094-9-136
   PubMedGoogle Scholar
• Seok SJ, Lee ES, Kim GT, et al. Blockade of CCL2/CCR2 signalling ameliorates diabetic nephropathy in db/db mice. Nephrol Dial Transpl. 2013;28(7):1700–1710. doi:10.1093/ndt/gfs555
   PubMed Web of Science ®Google Scholar
• Piotrowska A, Kwiatkowski K, Rojewska E, et al. Direct and indirect pharmacological modulation of CCL2/CCR2 pathway results in attenuation of neuropathic pain — in vivo and in vitro evidence. J Neuroimmunol. 2016;297:9–19. doi:10.1016/j.jneuroim.2016.04.017
   PubMed Web of Science ®Google Scholar
• Rivera S. Metalloproteinases in nervous system function and pathology: introduction. Cell Mol Life Sci. 2019;76(16):3051–3053. doi:10.1007/s00018-019-03172-8
   PubMedGoogle Scholar
• Chopra S, Overall CM, Dufour A. Matrix metalloproteinases in the CNS: interferons get nervous. Cell Mol Life Sci. 2019;76(16):3083–3095. doi:10.1007/s00018-019-03171-9
   PubMed Web of Science ®Google Scholar
• Opdenakker G, Abu El-Asrar A. Metalloproteinases mediate diabetes-induced retinal neuropathy and vasculopathy. Cell Mol Life Sci. 2019;76(16):3157–3166. doi:10.1007/s00018-019-03177-3
   PubMed Web of Science ®Google Scholar
• Wolf K, Te Lindert M, Krause M, et al. Physical limits of cell migration: control by ECM space and nuclear deformation and tuning by proteolysis and traction force. J Cell Biol. 2013;201(7):1069–1084. doi:10.1083/jcb.201210152
   PubMed Web of Science ®Google Scholar
• Bourboulia D, Stetler-Stevenson WG. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion. Semin Cancer Biol. 2010;20(3):161–168. doi:10.1016/j.semcancer.2010.05.002
   PubMed Web of Science ®Google Scholar
• Mishra M, Flaga J, Kowluru RA. Molecular mechanism of transcriptional regulation of matrix metalloproteinase-9 in diabetic retinopathy. J Cell Physiol. 2016;231(8):1709–1718. doi:10.1002/jcp.v231.8
   PubMedGoogle Scholar
• Chakrabarti S, Patel KD. Matrix metalloproteinase-2 (MMP-2) and MMP-9 in pulmonary pathology. Exp Lung Res. 2009;31(6):599–621. doi:10.1080/019021490944232
   Google Scholar
• Puolakkainen P, Koski A, Vainionpää S, et al. Anti-inflammatory macrophages activate invasion in pancreatic adenocarcinoma by increasing the MMP9 and ADAM8 expression. Med Oncol. 2014;31(3). doi:10.1007/s12032-014-0884-9
   Google Scholar
• Xu Y, Li Z, Jiang P, et al. The co-expression of MMP-9 and Tenascin-C is significantly associated with the progression and prognosis of pancreatic cancer. Diagn Pathol. 2015;10(1). doi:10.1186/s13000-015-0445-3
   Google Scholar
• Jimenez RE, Hartwig W, Antoniu BA, Compton CC, Warshaw AL, Fernandez-Del CC. Effect of matrix metalloproteinase inhibition on pancreatic cancer invasion and metastasis: an additive strategy for cancer control. Ann Surg. 2000;231(5):644–654. doi:10.1097/00000658-200005000-00004
   PubMedGoogle Scholar
• Grunwald B, Vandooren J, Locatelli E, et al. Matrix metalloproteinase-9 (MMP-9) as an activator of nanosystems for targeted drug delivery in pancreatic cancer. J Control Release. 2016;239:39–48. doi:10.1016/j.jconrel.2016.08.016
   PubMed Web of Science ®Google Scholar
• Awasthi N, Mikels Vigdal AJ, Stefanutti E, et al. Therapeutic efficacy of anti-MMP9 antibody in combination with nab-paclitaxel-based chemotherapy in pre‐clinical models of pancreatic cancer. J Cell Mol Med. 2019;23(6):3878–3887. doi:10.1111/jcmm.2019.23.issue-6
   PubMedGoogle Scholar
• Wang M, Tang X, Li L, et al. C1q/TNF-related protein-6 is associated with insulin resistance and the development of diabetes in Chinese population. Acta Diabetol. 2018;55(12):1221–1229. doi:10.1007/s00592-018-1203-2
   PubMed Web of Science ®Google Scholar
• Lei X, Seldin MM, Little HC, Choy N, Klonisch T, Wong GW. C1q/TNF-related protein 6 (CTRP6) links obesity to adipose tissue inflammation and insulin resistance. J Biol Chem. 2017;292(36):14836–14850. doi:10.1074/jbc.M116.766808
   PubMed Web of Science ®Google Scholar
• Qu HX, Cui L, Meng XY, et al. C1QTNF6 is overexpressed in gastric carcinoma and contributes to the proliferation and migration of gastric carcinoma cells. Int J Mol Med. 2019;43(1):621–629. doi:10.3892/ijmm.2018.3978
   PubMedGoogle Scholar
• Mikheev AM, Mikheeva SA, Severs LJ, et al. Targeting TWIST1 through loss of function inhibits tumorigenicity of human glioblastoma. Mol Oncol. 2018;12(7):1188–1202. doi:10.1002/mol2.2018.12.issue-7
   PubMedGoogle Scholar
• Pudova EA, Kudryavtseva AV, Fedorova MS, et al. HK3 overexpression associated with epithelial-mesenchymal transition in colorectal cancer. BMC Genomics. 2018;19(Suppl 3):113. doi:10.1186/s12864-018-4477-4
   PubMedGoogle Scholar
• Zhou T, Li H, Zhong H, Zhong Z. Relationship between transforming growth factor-β1 and type 2 diabetic nephropathy risk in Chinese population. BMC Med Genet. 2018;19(1). doi:10.1186/s12881-018-0717-3
   Google Scholar
• Nakano M, Kikushige Y, Miyawaki K, et al. Dedifferentiation process driven by TGF-beta signaling enhances stem cell properties in human colorectal cancer. Oncogene. 2019;38(6):780–793. doi:10.1038/s41388-018-0480-0
   PubMedGoogle Scholar
• Zhang Y, Zhu M, Sun Y, Li W, Wang Y, Yu W. Upregulation of lncRNA casc2 suppresses cell proliferation and metastasis of breast cancer via inactivation of the TGF-β signaling pathway. Oncol Res. 2019;27(3):379–387. doi:10.3727/096504018X15199531937158
   PubMed Web of Science ®Google Scholar
• Wang L, Su N, Zhang Y, Wang G. Clinical significance of serum lncRNA cancer susceptibility candidate 2 (CASC2) for chronic renal failure in patients with Type 2 diabetes. Med Sci Monitor. 2018;24:6079–6084. doi:10.12659/MSM.909510
   PubMed Web of Science ®Google Scholar
• Barrow AD, Palarasah Y, Bugatti M, et al. OSCAR is a receptor for surfactant protein D that activates TNF-α release from human CCR2+ inflammatory monocytes. J Immunol. 2015;194(7):3317–3326. doi:10.4049/jimmunol.1402289
   PubMed Web of Science ®Google Scholar
• Schultz HS, Guo L, Keller P, et al. OSCAR-collagen signaling in monocytes plays a proinflammatory role and may contribute to the pathogenesis of rheumatoid arthritis. Eur J Immunol. 2016;46(4):952–963. doi:10.1002/eji.201545986
   PubMedGoogle Scholar
• Takamura T, Honda M, Sakai Y, et al. Gene expression profiles in peripheral blood mononuclear cells reflect the pathophysiology of type 2 diabetes. Biochem Bioph Res Co. 2007;361(2):379–384. doi:10.1016/j.bbrc.2007.07.006
   PubMedGoogle Scholar
• Irvine KM, Gallego P, An X, et al. Peripheral blood monocyte gene expression profile clinically stratifies patients with recent-onset type 1 diabetes. Diabetes. 2012;61(5):1281–1290. doi:10.2337/db11-1549
   PubMedGoogle Scholar